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Abstract
To maintain homeostasis, the renin-angiotensin system (RAS) works to regulate the
cardiovascular, renal, respiratory, and neurological systems of the body. However, there is
evidence that abundant amounts of certain components of the RAS have detrimental effects and
enhance disease. Recent studies have proved that there is a lesser known RAS which acts to
counterbalance the classical RAS. To better understand their interaction, the effects of the
alternate RAS against the classical RAS in the homeostatic systems of the body are researched
and analyzed. The classical pathway employs these components: angiotensin converting enzyme
(ACE), angiotensin II (AngII), and angiotensin II type 1 receptor (AT1); the alternate pathway
involves: angiotensin converting enzyme 2 (ACE-2), angiotensin 1-7 (Ang1-7), and a Mas
receptor. There is growing affirmation that the novel alternate pathway RAS can play a
significant role in the advancement and progression of treatment for cardiovascular, renal,
neurological and respiratory diseases. Its components possess the potential to serve as templates
for the development of new drugs to mirror or enhance their interactions with the classical RAS
when necessary.
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The purpose of science is to aim to explain and understand complex processes and
interactions within nature, and discover new ones that can help humanity. Throughout the history
of medical studies, there have been countless cases focused on unraveling the intricate steps
involved in the human body’s care for itself. One of the heavily studied processes is the reninangiotensin system (RAS) which is a pivotal player in many homeostatic functions of the body.
The Classical Renin-Angiotensin System (RAS)
Angiotensinogen is the precursor of Angiotensin II (AngII) and is hydrolyzed by the
enzyme renin to form Angiotensin I (AngI). AngII is formed when the two carboxyterminal
amino acids of AngI are cleaved by angiotensin-converting enzyme (ACE). The RAS works to
regulate functions in the heart, kidneys, lungs, and brain.
Upon binding to the Ang II type 1 receptor (AT1R), Ang II stimulates vasoconstriction
and secretion of the steroid hormone, aldosterone, which mediates sodium reabsorption and
water retention. The RAS plays an important role in regulating blood volume and systemic
vascular resistance, which together influence cardiac output and arterial pressure. AngII, a major
member in the RAS, has direct and indirect effects on the heart. AngII has been known to act as
a growth factor in the heart. In isolated cardiac cells, angiotensin II induces hyperplasia
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(fibroblasts) or hypertrophy (myocytes) (Danser, 1996). It also enhances myocardial contractility
and metabolism. AngII directly regulates thirst and salt appetite via the central nervous system.
Several studies have found that the level of water intake correlates with the AngII plasma levels;
water intake is substantially reduced when the renin-angiotensin system is inhibited (Sica, 2001).
The RAS has its roots in the renal system as well. Renin in secreted from juxtaglomerular
cells in the kidneys. Ang II reduces single nephron glomerular filtration rate, glomerular plasma
flow and increases both afferent and efferent arteriolar resistance; it is basically one of the
overall regulators of renal hemodynamics (Kobori, 2007). Ultimately, the renal RAS is involved
in sodium balance, bodily fluid volume, and arterial blood pressure. The renal and cardiovascular
systems affect each other because when cardiac output declines, decrease in pressure from
reduced renal blood blow stimulates the baroreceptors of the kidney vessels, the juxtaglomerular
cells, and renin secretion is enhanced (Kobori, 2007).
As far as the RAS presence in the lungs, at a cellular level, angiotensin and aldosterone
activate oxidant stress signaling pathways that decrease levels of bioavailable nitric oxide,
increase inflammation, and promote cell proliferation, migration, extracellular matrix
remodeling, and fibrosis (Maron, 2014).
The Counter-regulatory Renin-Angiotensin System
The components of the alternate pathway involve angiotensin converting enzyme-2
(ACE-2), Angiotensin 1-7, and a Mas receptor. ACE-2, a homologue of ACE from the classical
RAS, functions as a carboxypeptidase that inactivates Ang II and is a negative regulator of the
system. The difference between ACE and ACE2 is that ACE2 cleaves only a single residue from
Ang I to generate Ang1-9, and a residue from Ang II to generate Ang1-7. In this way, ACE2
negatively regulates the RAS by inactivating Ang II and/or competing with ACE for the
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substrate Ang I. A study by Crackower et. al (2002) presents data confirming the function of
ACE2 as a regulator of the RAS modulating endogenous levels of Ang I and Ang II in mouse
hearts. Ang1-7, which possesses biological actions, is an angiotensin II peptide derivative where
the last carboxy amino acid, phenylalanine, is deleted. In early studies, Ang1-7 was initially
shown to mimic some effects of AngII including release of prostanoids and vasopressin. This is
old and disregarded information because the methods used to reach this conclusion have been
deemed incorrect. Recent studies show that Ang-(1-7) induces systemic and regional
vasodilation, diuresis and natriuresis, and exerts antiproliferative and antigrowth effects in
vascular smooth muscle cells, cardiac myocytes and fibroblasts as well as glomerular and
proximal tubular cells (Ferrario, 2014). The Mas Protooncogene encodes a protein with seven
hydrophobic transmembrane domains, considered to be an “orphan” G protein coupled receptor.
In a study by Santos and colleagues (2003), radioligand binding with autoradiography on kidneys
of Mas-deficient mice was conducted to demonstrate that the G protein coupled receptor, Mas,
binds Ang1-7 and is involved in its biological actions. Without this receptor, the AngII derivative
is essentially inactive. Knowing the role that each of these individuals take in the alternate axis is
critical in understanding how the counter-regulation works.
The Brain Renin-Angiotensin System
There is substantial evidence that activation of the RAS in the brain is involved in water
and sodium intake. Thirst and sodium depletion are monitored by osmoreceptors and/or sodium
receptors located at the periphery and AT1 receptors in the brain (Johnson, 2008). Additionally,
the activities of the brain RAS are achieved by influencing the autonomic nervous system, the
baroreflex sensitivity, and vasopressin (AVP) release (Speth et al., 2003). The CNS regulates
blood pressure by integrating neurohormonal signals to alter intake (water and salt) and output

Published by NSUWorks,

5

Mako: NSU Undergraduate Student Journal, Vol. 2020 [], Art. 2

ACE2/Ang1-7 MAS AXIS: THE COUNTER-REGULATOR OF THE CLASSICAL RENIN
ANGIOTENSIN SYSTEM
6

(renal excretion). In a way, the renin angiotensin system connects the cardiovascular, renal, and
CNS systems to keep the body’s homeostasis as leveled as possible. Besides knowledge on all of
these incredible findings, new research has revealed that there is more than just the traditional
renin-angiotensin pathway. The classical pathway employs these familiar components ACE,
AngII, and AT1 receptor, however, the alternate pathway involves deviations of some of these
and a different receptor. It is believed that the classical renin-angiotensin system is
counterbalanced by a prominent ACE2/Ang1-7/Mas Receptor activation, which is being studied
in depth to better understand how the body acts to maintain homeostasis between systems.
The Renin-Angiotensin System and Cardiovascular Disease
Many great discoveries have been made on the implications of the ACE2/Ang1-7/Mas
axis in diseases involving the classical renin-angiotensin system including cardiovascular
disease. Heart failure, a cumulative of previous conditions that weaken or stiffen the heart,
affects approximately 5.7 million adults in the United States, and cardiovascular disease is the
leading cause of death. Unraveling the involvement of the classical RAS has already made ways
for significant improvements in treatments for heart diseases. However, the introduction of the
countering system has provided more insight on how the body works to maintain its homeostasis.
A study by Tyrankeiwicz and colleagues (2017) was done on the activation pattern of the
ACE2/Ang1-7 and ACE/AngII pathways in course of heart failure. It was assessed by
multiparametric MRI in vivo in Tgαq*44 mice. The authors explained that “Tgαq*44 mice are a
transgenic model of slowly developing heart failure and peripheral endothelial dysfunction due
to cardiomyocyte-specific overexpression of G protein αq*44 (Tyrankeiwicz , 2017). They
analyzed systemic and local changes in ACE/ACE-2 balance in mice which were undergoing
heart failure. The pattern of changes in the heart and in the aorta was compatible with activation
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of ACE2 followed by activation of ACE. They found that the early stage of heart failure was
associated with upregulation of ACE2/Ang1-7 and the end stage by not only downregulation of
ACE2/Ang1-7 but also upregulation of the ACE/AngII pathway. ACE/ACE-2 balance seemed to
determine the decompensation of heart failure in this model. Additionally, in isolated hearts from
mRen2 (renin 2 tandem duplication of renin 1) transgenic rats, scientists conducting another
study showed that chronic ACE2 inhibition with the drug MLN-4760 for 28 days worsened
cardiac remodeling that was associated with increased cardiac Ang II levels (Ferrario, 2014).
These outcomes further enforce that the RAS involves two counter-regulatory axes
(ACE/AngII/AT1R) and ACE2/Ang1-7/Mas, and their balance is fundamental in maintaining
cardiovascular homeostasis. Hypertension is also one of the most common causes of
cardiovascular disease that affects billions of individuals worldwide. Ang II, from the classical
pathway, contributes to the regulation of blood pressure by influencing constriction of vascular
smooth muscle cells and sodium and water volume homeostasis as well as aldosterone secretion
(Ferrario, 2014). In an article by Castro and colleagues (2015), they studied the key role of
ACE2 and the vasoactive peptide Ang1-7 as counter-regulators of the ACE/Ang II/AT1R axis as
well as the biological properties that allow them to regulate blood pressure (BP) and
cardiovascular remodeling. They found that the ACE2/Ang-(1-7)/MasR axes has effects opposite
to those of the ACE/Ang II/AT1R axis, such as decreased proliferation and cardiovascular
remodeling, and increased production of NO and vasodilation (Castro, 2015). When
investigating ACE2 from a genetic view point in hypertensive rats, Crackower and colleagues
(2002) discovered that the Ace2 gene maps to a defined quantitative trait locus on the X
chromosome. A quantitative trait locus is a section of DNA which correlates with variation in a
phenotype and is usually linked to, or contains, the genes which control that phenotype. In all of
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the hypertensive rat strains, ACE2 mRNA and protein expression were significantly reduced and
AngII levels high (Crackower, 2002). ACE2 is such a key player in the counteraction of the
classical system in this case because it metabolizes the vasoconstrictive, hypertrophic,
proliferative angiotensin II into a more favorable angiotensin-(1-7) when necessary.
The Renin-Angiotensin System and Kidney Disease
Kidney disease is a major worldwide problem and patients with chronic kidney disease
(CKD) are at increased cardiovascular risk. CKD is characterized by enhanced activity of the
RAS which progresses to both cardiac and renal injury. Factors beyond the traditional RAS are
involved in the progression of the disease. According to Burrel et. al (2004), ACE2 acts in a
counter-regulatory manner to ACE, modulating the balance between vasoconstrictors and
vasodilators within the heart and kidney, and playing a significant role in regulating cardio and
renal function. Additional studies show that ACE2 has renoprotective effects because when
ACE2 is deleted or inhibited, pathology ensues (Burrel, 2004). Cao et. al (2012), investigated
heart and kidneys in mice that were diseased (induced by subtotal nephrectomy where they cut
out most but not all of the nephrons in the kidneys). The scientists found that acute renal mass
reduction with nephron removal led to reduction in renal ACE2 activity, but marked increase in
cardiac ACE2 activity. This is one factor that enforces the tie between renal and cardiac health.
As ACE2 production is depleted because of the lack of nephrons, the heart is releasing more
ACE2 to compensate. Since the nephrons are the functional units of the kidney that handle
excreting excess water concentration in the blood, their absence means an increase in blood
volume and therefore blood pressure. Vasodilation reduces vascular resistance to blood flow and
therefore lowers blood pressure. This may be why the heart increases its ACE2 activity which is
known to have dilatory functions. Although quite intriguing results, it is unknown if these

https://nsuworks.nova.edu/mako/vol2020/iss1/2

8

Dorsainval: ACE2/Ang1-7 MAS AXIS: THE COUNTER-REGULATOR OF THE CLASSICAL RENI

ACE2/Ang1-7 MAS AXIS: THE COUNTER-REGULATOR OF THE CLASSICAL RENIN
ANGIOTENSIN SYSTEM
9

conditions persist long term. The authors suggest that adjunctive therapies to ACE inhibition,
such as strategies that lead to increases in ACE2 activity over and above levels seen in normal
physiology, may be needed in order to combat the cardio-renal complications of chronic kidney
disease.
The Renin-Angiotensin System and Lung Disease
Pulmonary fibrosis is a progressive and fatal lung disease characterized by chronic
inflammation, the migration and proliferation of fibroblasts, the accumulation of the extracellular
matrix (ECM), and remodeling of the lung parenchyma (functional tissue). Currently, there are
no effective antifibrotic therapies for pulmonary fibrosis. As expressed in an article by Meng
et.al (2013), a growing body of evidence indicates that AngII plays a key role in the initiation
and the maintenance of lung fibrosis, in other words, it negatively effects lung recovery by
enhancing fibrosis, increasing inflammation and other factors. The recent discovery of the
ACE2/Ang-(1-7)/Mas axis offers an alternative approach for counter-regulating the
ACE/AngII/AT1R axis to produce more beneficial effects. Ang(1-7) has been shown to
counteract the detrimental effects of AngII in the lungs (Meng, 2013). The ACE2/Ang-(1-7)/Mas
axis may potentially offer a novel therapeutic strategy for pulmonary fibrosis. However, the
exact molecular mechanism by which the ACE2/Ang-(1-7)/Mas axis protects against pulmonary
fibrosis remains unclear. Affirmation of a beneficial role of ACE-2/ANG1-7 is strengthened by
in vivo studies of animals that utilized genetic manipulation of ACE-2 or specific inhibitors of
ACE-2 to establish a protective role of the enzyme (Uhal, 2014). Previous work by Uhal et al.
showed that ACE-2 is protective against experimental fibrosis, but is down-regulated in both
human lung fibrosis and experimental lung fibrosis in animal models. More recently, the same
researchers analyzed lung biopsy specimens from humans and rats with fibrosis and
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demonstrated that the mRNA transcript for ACE2 was producing low levels of protein product
which in-turn meant decreased levels of enzymatic activity. Additional findings revealed that
administration of experimental Ang1-7 and ACE2 reduced collagen deposition, decreased AT1
receptor protein levels in the rat lungs, and that protective effects against lung fibrosis were also
obtained by overexpression of ACE-2 (Uhal, 2014).
Novel Aspects of the Brain Renin-Angiotensin System and Neurodegenerative Disease
Besides its control of systemic blood pressure, it has been clarified that the local brain
RAS plays an important role in a variety of neuronal functions. Recent clinical trials have
revealed that administration of AT1 Angiotensin receptor blockers (ARBs) not only lowered
blood pressure but only prevented the onset of stroke (Mogi, 2011). Further studies have shown
that the inhibition of different components of the classical RAS, specifically ACE and the AT1
receptor, has neuroprotective effects on the brain and prevents other detrimental events like
epilepsy (Becari, 2010). Similarly, stimulation of the AT2 receptor brings neuronal regeneration
after injury and the inhibition of pathological progression. Ang-(1–7) mediates its
antihypertensive effects by stimulating the synthesis and release of vasodilator prostaglandins
and nitric oxide (Albrecht, 2006). In another recent study by Mecca and associates (2011),
central administration of ANG-(1–7) reduced neurological deficits and infarct size in a rat model
of ischemic stroke, demonstrating evidence of the special cerebroprotective properties of this
peptide.
The Counter-regulatory Renin-Angiotensin System: Novel Therapeutic Approaches
The newly uncovered ACE2/Ang-(1-7)/Mas axis provides possibility for new treatments
for RAS related diseases like pulmonary fibrosis, hypertension, heart failure, and kidney disease.
Many great treatments have already been devised to suppress the classical system which is
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beneficial because they give way for the alternate system to better perform. However, drugs to
directly interact with the new system are on the rise. The counter-regulatory axes of renin
angiotensin system play an important role in the cardiovascular repair. A study by Singh et. al
(2015) suggests that ACE2/Ang-(1-7)/Mas pathway stimulates functions of CD34+ (a common
cell-surface marker) cells that are reparative and regenerative of the cardiovascular framework.
New evidence has shown that ACE2 and Mas receptor are actually expressed in these cells
which are vasoprotective (Singh, 2015). These findings imply that pharmaceutical activation of
ACE2/Ang-(1-7)/Mas axis is a promising approach for enhancing the reparative outcomes
present in cell-based therapies. Knowing the benefits that lie in the counterregulatory powers of
the alternate system against the classical system, Patel and colleagues (2016) introduced a wellstudied tool to enhance ACE2 action: recombinant human ACE2 (rhACE2). In a randomized,
placebo-controlled study, these scientists administered intravenous rhACE2 to healthy human
subjects and found that it was well-tolerated. RhACE2 provided beneficial effects against Ang
II-induced heart failure. Patients that had suppressed Ang-(1-7) and rising Ang II amounts
experienced worsened HF symptoms and longer hospitalization. Whereas once the rhACE2 was
given, Ang1-7 levels increased and AngII leveled (Patel, 2016). Thus, using rhACE2 as a
therapy is very much a viable option. Several ACE2 activators and Ang 1–7/MasR agonists have
been developed. Also, gene therapy approaches could be utilized to achieve a more tissuespecific delivery of ACE2/Ang 1–7. The stimulation of the ACE2/Ang-(1–7)/Mas axis has been
successfully used to prevent and reverse pulmonary hypertension and fibrosis in animals. ACE2
activation or induction of ACE2 overexpression by gene transfer efficiently prevented and, more
importantly, reversed the increase of right systolic ventricular pressure (RSVP), pulmonary
fibrosis, and imbalance of the RAS (Patel, 2016). Novel approaches, including oral ACE2 and
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Ang 1–7 biencapsulated in plant cells, have been designed and used in preclinical studies,
showing promising antihypertensive, anti-inflammatory and cardioprotective effects. This is one
of the most significant findings recently because a system to generate human ACE2 and Ang-(17) within plant chloroplasts using transplastomic technology has been invented. The native
human ACE2 cDNA and synthetic Ang-(1-7) DNA sequences were cloned into a chloroplast
transformation vector, and for efficient delivery of the proteins into circulation, a carrier protein,
cholera nontoxic B subunit (CTB), was fused to the N terminal of both therapeutic proteins
(Shenoy, 2014). Doing this facilitates their transmucosal delivery by binding to certain receptors
(GM1) present on the intestinal epithelial cells. Additional modifications were made between
CTB and the therapeutic proteins to eliminate steric hindrance and aid systemic release of the
therapeutic proteins after they have entered the system via ligand–receptor complex formation on
the surface of epithelial cells (Shenoy, 2014). This approach by Shenoy and colleagues is
remarkable because it develops a system of a plant-based oral delivery which will overcome
challenges like repetitive intravenous dosing, cost of manufacturing protein stability, and patient
compliance. It is the next step in being able to exploit the alternate system to reach its fullest
beneficial potential. This study provides proof that the creation of a low-cost plant based oral
delivery system for ACE2 or Ang-(1-7) bioencapsulated in plant chloroplasts is most certainly
possible (Shenoy, 2014).
Conclusions and Future Directions
The complexity of the RAS is far beyond what was suspected years ago and there are still
many unanswered questions about the novel RAS pathway. Learning about this counteracting
pathway gives more insight on how the body is equipped to keep its equilibrium. There is
growing evidence that the novel components of the RAS [Ang-(1–7), ACE2, and Mas] may be a
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significant piece to the advancement and progression of treatment for cardiovascular, kidney,
neurological and respiratory diseases. Additionally, because of their counterregulatory actions,
they serve as templates for the development of new drugs to mirror or enhance their interactions
with the classical renin angiotensin system when necessary.
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